3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
2121
Neoplasms, Plasma Cell
505
Lymphoma
354
Lymphoma, Non-Hodgkin
334
Hodgkin Disease
329
Leukemia, Lymphocytic, Chronic, B-Cell
307
Precursor Cell Lymphoblastic Leukemia-Lymphoma
299
Leukemia
290
Leukemia, Myeloid, Acute
270
Myelodysplastic Syndromes
263
Lymphoma, Mantle-Cell
228
Lymphoma, Follicular
224
Lymphoma, Large B-Cell, Diffuse
216
Lymphoma, B-Cell, Marginal Zone
206
Burkitt Lymphoma
201
Recurrence
188
Myeloproliferative Disorders
182
Lymphoma, Large-Cell, Immunoblastic
182
Immunoglobulin Light-chain Amyloidosis
162
Primary Myelofibrosis
153
Leukemia, Myeloid, Chronic-Phase
152
Leukemia, Myeloid, Accelerated Phase
143
Lymphoma, T-Cell, Cutaneous
140
Leukemia, Myelomonocytic, Chronic
133
Blast Crisis
131
Mycosis Fungoides
126
Sezary Syndrome
125
Congenital Abnormalities
122
Waldenstrom Macroglobulinemia
121
Leukemia, Hairy Cell
110
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Purpura, Thrombotic Thrombocytopenic
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn